Abbott Laboratories (ABT)
$94.47 1.43 (1.54%)
14:31 EDT ABT Stock Quote Delayed 30 Minutes
Previous Close $93.04
Market Cap 165.62B
PE Ratio 449.86
Volume (Avg. Vol.) 2.14M
Day's Range 93.13 - 95.62
52-Week Range 61.61 - 100.00
Dividend & Yield 1.12 (1.19%)
ABT Stock Predictions, Articles, and Abbott Laboratories News
- From InvestorPlace
- From the Web
Abbott Labs (ABT) stock was down more than 2% on Wednesday despite the fact that the company's fourth-quarter earnings reached expectations.
IBM, Abbott Labs, Papa John's, Starbucks and Disney round out our must-see stock charts for Thursday. Here's why.
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
These consumer stocks offer generous, growing dividends and should return to a growth trajectory based on new business lines.
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
ABT stock was down on Wednesday after the healthcare company released its earnings report for the third quarter of the year.
The short-term nature of the stock markets makes it hard for companies to think bigger picture -- but these seven best long-term stocks do.
There are dividend stocks, and then there are dividend aristocrats. These ten names are the income producers you rarely have to worry about.
We take a closer look at 10 stocks RBC Capital has pinpointed as the leaders and laggards of the future. These are the stocks that are set to outperform in 2025, but also the stocks facing the biggest risks from our ever-changing society.
Abbott Laboratories (ABT) stock was up on Wednesday following the release of its earnings report for the second quarter of 2018.
Stock charts of United Technologies, Abbott Laboratories and Leggett & Platt have earned a closer look as bullish trading prospects this morning.
Abbott Laboratories (ABT) stock as down on Wednesday despite the health care company reporting an earnings beat for the first quarter of 2018.
The Buy for Abbott Laboratories (ABT) this week is based on the latest relative pricing of its shares and news.
With recent market fluctuations, these 7 stocks now make particularly compelling investing opportunities -- and each boasts a Street consensus rating of 'Strong Buy.'
Portfolio Grader currently ranks ABT as a Buy. This analytical tool evaluates stocks by employing proprietary fundamental and quantitative analytical. This represents no change from the previous week and is the same ranking ABT has had from Portfolio Grader for 4 months.
Here are five stellar stocks to keep a close eye on as we head deeper into earnings season. All these stocks are due to report earnings in the next couple of weeks. You can feel good about these stock picks as each of these five stocks has a 'Strong Buy' consensus rating from the Street's best-performing analysts.
Sunday’s Midday Movers: EKSO BIONICS (EKSO), Cleveland-Cliffs (CLF), United Airlines Holdings (UAL), Tesla (TSLA), United States Steel (X)
From Analyst Ratings
So far Sunday, July 12, NASDAQ is up 2.3% and the S&P is up 3.28%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; EKSO BIONICS (EKSO – Research Report), Cleveland-Cliffs (CLF – Research Report), United Airlines Holdings (UAL – Research Report), Tesla (TSLA – Research Report) and United
From Market News Video
Navellier RatingsPowered by Portfolio Grader